CBISinactive

CANNABIS SCIENCE, INC.

Healthcare·Oncology·Pre-clinical
OncologyInfectious Disease
4.0/10

BioSniper Score

4-factor signal

Market Cap

—

Cash Runway

2.2 mo

Lead Asset

nanogold (Preclinical)

Next Catalyst

—

CANNABIS SCIENCE, INC.: 1 pipeline candidate · 1 clinical trial · Updated within the last hour.

Go deeper on CANNABIS SCIENCE, INC. with Spotter

Ask follow-up questions and run a full multi-agent deep dive on CBIS — live, with citations.

Ask Spotter

Score breakdown4-factor signal · derived from public data

Cash Runway0.6

2.2 months

Financial Health10.0

0% dilution

Pipeline Maturity2.0

Lead: Preclinical

Pipeline Breadth3.3

1 candidate

Catalyst MomentumN/A

N/A

Insider SignalN/A

N/A

Key Financialsas of September 30, 2017

Cash

$29K

Quarterly Burn

$219K

Revenue

$2K

Cash Runway vs Catalysts

Tracked catalysts land within the current projected cash runway.

Cash ends ~Aug 2026
Today~7 mo out
Catalyst within runway

Pipeline (1 candidate)

DrugPhase
nanogoldPreclinical

Frequently asked questions

What is CANNABIS SCIENCE, INC.'s lead drug candidate?

CANNABIS SCIENCE, INC.'s most advanced tracked candidate is nanogold (Preclinical) for HIV.

What therapeutic areas does CANNABIS SCIENCE, INC. focus on?

CANNABIS SCIENCE, INC. develops therapies across Oncology, Infectious Disease.

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.

Get the full picture on CANNABIS SCIENCE, INC.

Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.

Start Free AnalysisBrowse Calendar